Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Glaucoma Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Glaucoma Therapeutics Market Is Forecast to Show a Decline in Growth Rate Due to a String of Patent Expiries until 2018
By: Rajesh Gunnam depletion over the next few years due to a string of patent expiries for major marketed products such as Xalatan (latanoprost) The glaucoma therapeutics market will be subjected to generic erosion, which will impact the overall valuation of the market. An important fact to note alongside this is that the late stage products which are expected to enter the market are either me-too or product extensions, with safety and efficacy profiles either equivalent to or only slightly better than the marketed drugs. These drugs are targeted to provide symptomatic relief to glaucoma patients but may not treat the underlying cause of the disorder. This in turn may not have a significant impact on the glaucoma therapeutics market in the coming years. The key factor which will drive the market in the future will be an increasing number of incidence cases. As a result, generics are predicted to govern the market for glaucoma drugs over the next few years. There is a high degree of Research and Development (R&D) activity in the early stages of development in the glaucoma therapeutics pipeline. The new drugs in the early stage pipeline with novel mechanisms of action are targeting the cause of the disease rather than providing symptomatic relief. However, being in the early stages of development, these drugs are not expected to impact the market during the forecast period through to 2018. The CAGR for 2005 to 2010 was 3.0% and is expected to witness a significant erosion to reach a CAGR of 0.6% between 2010 and 2018 because of the impact of generics entering the market and there being no major pipeline products which could drive the market significantly. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData has analyzed the current marketing activities of major players in terms of their product launching plans and promotions across global geographies. Merck’s Saflutan, which was originally acquired from Santen Pharmaceuticals in Japan, is currently under evaluation for approval in the US and Europe. An increasing number of players in the ophthalmic market are aggressively planning strategies to cash in on the major untapped Japanese market, and this trend is likely to continue over the next few years. As an example, SNJ-2022 by Senju Pharmaceutical has been filed for NDA (New Drug Approval) approval in Japan, which is likely to introduce the drug during the forecast period. There are other market players which are hoping to gain entry into the glaucoma therapeutics market in the US and the European countries with their products which are currently in NDA filed stage or in Phase III stage trials, which include Saflutan (NDA-filed), by Merck, and DuoTrav APS, by Alcon/Novartis GlobalData, the industry analysis specialist, has released its new report, “Glaucoma Therapeutics Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global glaucoma therapeutics market. The report identifies the key trends shaping and driving the global glaucoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global glaucoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number